PRALUENT 75 MG — DIN 02453819
ALIROCUMAB : 75 MG · SANOFI-AVENTIS CANADA INC · SOLUTION · wholesale supply in Canada
Health Canada status: MARKETED
What is PRALUENT?
PRALUENT 75 MG contains ALIROCUMAB : 75 MG. It is listed in the Health Canada Drug Product Database under DIN 02453819, held by SANOFI-AVENTIS CANADA INC, supplied as SOLUTION for SUBCUTANEOUS administration. Health Canada currently lists it as marketed, status dated 18-May-2016. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is PRALUENT used for?
Prevention of cardiovascular events in adults with established CV disease; reduction of LDL-C in adults with primary hyperlipidemia (heterozygous familial and non-familial).
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Alirocumab cost around the world?
Alirocumab is listed on 11 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Austria publishes a KVP (Kassenverkaufspreis); Czechia publishes a max producer price (ex-factory); Greece publishes a producer price (ex-factory). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| Saudi Arabia | public | 5 | 9 | SAR███.██ |
| Czechia | max producer price (ex-factory) | 1 | 6 | CZK███.██ |
| Greece | producer price (ex-factory) | 6 | 6 | EUR███.██ |
| Luxembourg | reimbursement | 6 | 6 | EUR███.██ |
| Slovakia | categorised final price | 4 | 6 | EUR███.██ |
| Italy | prezzo al pubblico (classe A) | 5 | 5 | EUR███.██ |
| Romania | max producer price | 3 | 5 | RON███.██ |
| Iceland | max wholesale | 1 | 4 | ISK███.██ |
| United Arab Emirates | public | 3 | 3 | AED███.██ |
| Austria | KVP (Kassenverkaufspreis) | 3 | 3 | EUR███.██ |
| South Africa | single exit price | 2 | 2 | ZAR███.██ |
55 pack listings across 39 brand entries and 10 price bases, refreshed 05 Sep 2026. Ranges span every Alirocumab pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Alirocumab in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
Only one market authorization holder has a Canadian DIN containing Alirocumab — 5 DINs, of which 3 are currently marketed. There is no second Canadian source today, so a supply interruption on this holder has no domestic substitute at the same molecule.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| SANOFI-AVENTIS CANADA INC | 5 | 3 | PRALUENT | Sourceable in Canada |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 75 MG |
|---|---|
| Dosage form | SOLUTION |
| Route | SUBCUTANEOUS |
| Pack configuration (monograph) | 75 or 150 mg PFP: 1, 2, or 6 per carton. 300 mg PFP: 1 or 3 per carton. Supplied in Type 1 clear glass syringes. |
| Storage | Store in refrigerator (implied by instructions to remove 30-45 mins before use to reach room temperature). (Note: Specific temp range not in snippet). |
| Shipping class | Cold chain — validated shipper with temperature monitoring |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Cold chain. This product is stored refrigerated. Nexara ships it on a validated cold chain with temperature monitoring; a delivery address that cannot receive and store it at 2–8 °C on arrival must be flagged before the order is placed.
Substance and classification
| Active substance | Alirocumab |
|---|---|
| ATC code | C10AX14 |
| AHFS class | 24:06.24 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02453819 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2453819 |
| Brand name | PRALUENT |
| Generic / active ingredient | ALIROCUMAB : 75 MG |
| Market authorization holder | SANOFI-AVENTIS CANADA INC |
| Health Canada schedule | Prescription |
| ATC code | C10AX14 |
| ATC anatomical main group | C — Cardiovascular system |
| ATC therapeutic subgroup | C10AX |
| Current status | MARKETED |
| Status date | 18-May-2016 |
| Original market date | 2016-05-18 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Starting dose: 75 mg subcutaneously every 2 weeks or 300 mg every 4 weeks. Measure LDL-C within 4-8 weeks; may adjust to maximum 150 mg every 2 weeks if response is inadequate.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Hypersensitivity to this drug or to any ingredient in the formulation, including any non-medicinal ingredient, or component of the container.
Warnings and precautions
Serious hypersensitivity reactions (angioedema, rash, vasculitis) reported. Discontinue if serious reactions occur. Long-term effects of very low LDL-C are unknown.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
3 of 5 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| PRALUENT | 150 MG | SOLUTION | SANOFI-AVENTIS CANADA INC | MARKETED | 02453835 |
| PRALUENT | 300 MG / 2 ML | SOLUTION | SANOFI-AVENTIS CANADA INC | MARKETED | 02547732 |
| PRALUENT | 75 MG | SOLUTION | SANOFI-AVENTIS CANADA INC | CANCELLED POST MARKET | 02453754 |
| PRALUENT | 150 MG | SOLUTION | SANOFI-AVENTIS CANADA INC | CANCELLED POST MARKET | 02453762 |
2 · Same class — other molecules in ATC C10AX
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Ezetimibe | ACH-EZETIMIBE · ACT EZETIMIBE · AG-EZETIMIBE · APO-EZETIMIBE · +19 more | 26 | 18 | Yes |
| Alirocumab | PRALUENT | 5 | 3 | Yes |
| Lomitapide | JUXTAPID | 3 | 3 | Yes |
| Omega-3-Triglycerides Incl. Other Esters And Acids | FLEX 500 · HERBALIFELINE · OMEGA-3 · VASCEPA | 4 | 1 | Yes |
| Evolocumab | REPATHA | 2 | 1 | Yes |
| Inclisiran | LEQVIO | 1 | 1 | Yes |
| Evinacumab | EVKEEZA | 1 | 1 | Yes |
| Dextrothyroxine | CHOLOXIN - TAB 4MG · CHOLOXIN TAB 2MG · CHOLOXIN TABLET 4MG | 4 | 0 | Not in Canada |
| Omega-3-Triglycerides, Combinations | OMEGA-3 FACTORS WITH VITAMIN E | 1 | 0 | Not in Canada |
| Probucol | LORELCO | 1 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC C10A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| C10AA | Atorvastatin · Cerivastatin · Fluvastatin · Lovastatin · Pravastatin · +2 more | 759 | 286 |
| C10AB | Bezafibrate · Clofibrate · Fenofibrate · Gemfibrozil | 87 | 13 |
| C10AC | Colesevelam · Colestipol · Colestyramine | 29 | 6 |
| C10AD | Nicotinic Acid | 6 | 0 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.